Pharmaceutical

Cyclacel Pharmaceuticals (NASDAQ:CYCC) (NASDAQ:CYCCP) a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced results from a Phase 1 safety, pharmacokinetic and pharmacodynamic study of CYC065, the Company’s novel cyclin dependent kinase, or CDK2/9 inhibitor, in patients with advanced …

Cyclacel Pharmaceuticals (NASDAQ:CYCC) (NASDAQ:CYCCP) a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced results from a Phase 1 safety, pharmacokinetic and pharmacodynamic study of CYC065, the Company’s novel cyclin dependent kinase, or CDK2/9 inhibitor, in patients with advanced cancers. Data were reported at an oral presentation on Sunday, April 15, at 3:35 PM CT at the American Association for Cancer Research (AACR) Annual Meeting held in Chicago, IL.

As quoted in the press release:

“Our findings show that CYC065 is effective in suppressing the cancer survival protein Mcl-1 in peripheral blood for at least 24 hours,” said Geoffrey Shapiro, MD, PhD, Director, Early Drug Development Center, Dana-Faber Cancer Institute and Professor of Medicine, Harvard Medical School, Boston, MA. “The durable target inhibition achieved at the recommended Phase 2 dose provides a rationale to further evaluate this novel agent in Mcl-1, MYC or cyclin E amplified tumors.”

“The clinical data support biomarker-driven clinical development of CYC065 in selected patient populations,” said Spiro Rombotis, President and Chief Executive Officer of Cyclacel. “In addition, the durable suppression of the Mcl-1 survival protein presents an exciting opportunity to combine CYC065 with other agents targeting the apoptosis pathway, such as venetoclax. We will soon be starting a clinical study testing CYC065 in combination with venetoclax in patients with relapsed/refractory chronic lymphocytic leukemia.”

Click here to read the full press release.

Featured

MARKETS

Markets
TSX21224.25-50.32
TSXV895.91+5.05
DOW35305.16-63.31
S&P 5004574.48-2.63
NASD14489.39-17.51
ASX7408.80-8.50

COMMODITIES

Commodities
Gold1840.05+25.98
Silver24.02+0.56
Copper4.47+0.09
Palladium2007.37+121.36
Platinum1034.99+53.99
Oil87.27+1.84
Heating Oil2.65+0.03
Natural Gas4.13-0.15

DOWNLOAD FREE REPORTS

×